+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xyrem"

United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis - Product Thumbnail Image

United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis

  • Report
  • July 2025
  • 200 Pages
  • United States
From
XYREM (Sodium oxybate) Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

XYREM (Sodium oxybate) Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030 - Product Thumbnail Image

Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030

  • Report
  • January 2024
  • 172 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Xyrem is a central nervous system (CNS) drug used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of sleep. Xyrem is a brand name for sodium oxybate, a form of gamma-hydroxybutyrate (GHB). It is a sedative-hypnotic drug that works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain, which helps to reduce the symptoms of narcolepsy. Xyrem is a Schedule III controlled substance and is only available through a restricted distribution program. Xyrem is manufactured by Jazz Pharmaceuticals, a specialty pharmaceutical company based in Ireland. Other companies in the Xyrem market include Teva Pharmaceuticals, which markets a generic version of the drug, and Sunovion Pharmaceuticals, which markets a brand-name version of the drug. Show Less Read more